Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity

Maria Laura Canale, Andrea Camerini, Alda Huqi, Alessio Lilli, Irma Bisceglia, Iris Parrini, Chiara Lestuzzi, Jacopo Del Meglio, Sara Donati, Elio Venturini, Alessandro Sgambato, Luigi Tarantini, Domenico Amoroso, Giancarlo Casolo

Research output: Contribution to journalArticlepeer-review


BACKGROUND/AIM: Cardiovascular risk factors (CVRFs) predict cardiotoxicity in cancer patients but their role in late cardiac toxicity is less clear.

PATIENTS AND METHODS: This was a retrospective analysis of patients treated with anthracyclines (A) and/or trastuzumab (T) and a correlation with early (≤5 years) or late (>5 years) cardiac toxicity, and baseline CVRFs and CVRFs at toxicity time.

RESULTS: A total of 610 patients were included, 422 with (Group A) and 188 without (Group B) baseline CVRFs. In group A toxicity incidence was 4.7% with all events during treatment or immediately after [mean onset time 0.7 years (range=0.2-1.6)]. Events rate was 3.2% in group B with all events after five years [mean time onset 6.9 years (range=5.2-7.5)]. All group B patients who developed late cardiac toxicity presented with CVRFs at the time of toxicity not reported before.

CONCLUSION: CVRFs could predict late cardiac toxicity and their control should be part of the survivorship program.

Original languageEnglish
Pages (from-to)5741-5745
Number of pages5
JournalAnticancer Research
Issue number10
Publication statusPublished - Oct 2019


  • Adult
  • Aged
  • Anthracyclines/administration & dosage
  • Antineoplastic Agents, Immunological/adverse effects
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Breast Neoplasms/drug therapy
  • Cardiotoxicity/etiology
  • Female
  • Heart Diseases/chemically induced
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Retrospective Studies
  • Risk Factors
  • Trastuzumab/administration & dosage


Dive into the research topics of 'Cardiovascular Risk Factors and Timing of Anthracyclines and Trastuzumab Cardiac Toxicity'. Together they form a unique fingerprint.

Cite this